MorphoSys AG (WBO:MOR) Total Liabilities : €1,977.3 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is MorphoSys AG Total Liabilities?

MorphoSys AG's Total Liabilities for the quarter that ended in Dec. 2023 was €1,977.3 Mil.

MorphoSys AG's quarterly Total Liabilities declined from Jun. 2023 (€2,110.83 Mil) to Sep. 2023 (€0.00 Mil) but then increased from Sep. 2023 (€0.00 Mil) to Dec. 2023 (€1,977.26 Mil).

MorphoSys AG's annual Total Liabilities declined from Dec. 2021 (€2,311.38 Mil) to Dec. 2022 (€2,239.52 Mil) and declined from Dec. 2022 (€2,239.52 Mil) to Dec. 2023 (€1,977.26 Mil).

MorphoSys AG Total Liabilities Historical Data

The historical data trend for MorphoSys AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MorphoSys AG Total Liabilities Chart

MorphoSys AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

101.74

1,038.19

2,311.38

2,239.52

1,977.26

MorphoSys AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Liabilities	Get a 7-Day Free Trial															2,239.52	2,132.48	2,110.83	-	1,977.26

MorphoSys AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

MorphoSys AG's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	264.311	+	(621.882	+	1084.519
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	6.55	+	0)
	=	1,977.3

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2026.311	-	49.049
	=	1,977.3

MorphoSys AG's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	264.311	+	(621.882	+	1084.519
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	6.55	+	0)
	=	1,977.3

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	2026.311	-	49.049
	=	1,977.3

MorphoSys AG Total Liabilities Related Terms

Thank you for viewing the detailed overview of MorphoSys AG's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

MorphoSys AG (WBO:MOR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MorphoSys AG (WBO:MOR) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

MPSYF:USA MOR:USA 1MOR:Italy MORd:UK 0NDV:UK MOR:Germany

Address

Semmelweisstrasse 7, Planegg, BY, DEU, 82152

Website

https://www.morphosys.com

MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.